Sign in or Sign up

User ID


Remember me - forgot password


Sign up or Sign in

Name (in full)

Email address


Confirm Password




Nifurtimox is the first compound that proved effective in human therapy of the South American trypanosomiasis caused by Trypanosoma cruzi. Chemically itidentified as 3-methyl-N-[(5-niro-2-furanyl) methylene]-4-thiomorpholinamine-1, 2-dioxide. Nifurtimox is tripanocidal against both amastigote and tripomasigote form of Trypanosoma cruzi. iteffective against both acute as well as chronic phase of infection. it is prepared by chemical synthesis. itadministerd orally.


Primary Characterstics

Molecular Structure of Nifurtimox
. It is of Synthetic origin and belongs to Nitrofurane. It belongs to Antiparasitic pharmacological group on the basis of mechanism of action. The Molecular Weight of Nifurtimox is 287.30.



Nifurtimox is primarily indicated in conditions like Leishmaniasis, Onchoceriasis, Trypanosomiasis.


Nifurtimox is contraindicated in conditions like Convulsions,Cerebral impairment.

Drug Interactions

No data regarding the interactions of Nifurtimox was found.

Interference in Pathology

No data regarding the pathological interferences produced by Nifurtimox is available.

Side Effects

The severe or irreversible adverse effects of Nifurtimox, which give rise to further complications include Convulsions, Insomnia, Psychosis, Disorientation, Disturbance of equilibrium.

Nifurtimox produces potentially life-threatening effects which include Leucopenia. which are responsible for the discontinuation of Nifurtimox therapy.

The signs and symptoms that are produced after the acute overdosage of Nifurtimox include Excitation, Gastralgia.

The symptomatic adverse reactions produced by Nifurtimox are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Anorexia, Myalgia, Urticaria, Skin rash, Paresthesias, Neuralgia, Morbiliform, Exanthema, dizziness.

Available Brands

No Brands Available.


Nifurtimox's dosage details are as follows:
Dose Single Dose Frequency Route Instructions

Adult Dosage

8 to 10 mg/kg9 (9)24 hourlyPO-

Paedriatic Dosage ( 20 Kg. )

15 to 20 mg/kg18 (17.5)24 hourly

Neonatal Dosage ( 3 Kg. )

No data regarding the neonatal dosage details of Nifurtimox is available.

High Risk Groups

Drug should not be given to Pregnant Mothers, and patients suffering from Kidney dysfunction.

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Warning / Precautions

The drug should be used with extreme caution in the pregnant or the breast feeding women and children <1year old.

Storage Conditions

comments powered by Disqus